What Blood Tests Show Leukemia: CBC, Smear & More

Leukemia is usually first suspected from a routine complete blood count, or CBC, which measures white blood cells, red blood cells, and platelets. An abnormal CBC alone cannot confirm a diagnosis, but it is the test that most often sets the diagnostic process in motion, sometimes catching leukemia before a patient has any symptoms at all. From there, a cascade of increasingly specialized blood tests fills in the picture: peripheral blood smears, flow cytometry, genetic analyses, and newer molecular techniques each answer different questions about the disease.

The Complete Blood Count as a Starting Point

A CBC is the most commonly ordered blood test in medicine, and its role in leukemia detection is often unintentional. Because it quantifies white blood cells, red blood cells, and platelets, it effectively gives a snapshot of bone marrow function, which is exactly where most leukemias originate.¹ Doctors ordering a CBC for fatigue, a preoperative check, or a routine physical may stumble across alarming numbers that point toward a blood cancer nobody was looking for.

The patterns vary by leukemia type, but a few hallmarks stand out. A dramatically elevated white blood cell count is the most classic finding, though some leukemias actually present with low white counts. Anemia (low hemoglobin) and low platelet counts are common across most types because leukemic cells crowd out normal blood-cell production. What matters is not just whether a single value is high or low but the combination: a sky-high white count alongside low hemoglobin and low platelets is a much more concerning pattern than any one of those abnormalities alone.

Different leukemia types produce different CBC fingerprints. In adults, chronic myeloid leukemia (CML) often shows a very high white count with preserved platelet levels. In children, acute lymphoblastic leukemia (ALL) is the most common type, and it tends to cause more severe drops in platelets compared to what is typically seen in adult CML.² These patterns help a clinician decide how urgently to pursue further testing, but no CBC pattern is specific enough to name the exact diagnosis on its own.

What a Peripheral Blood Smear Adds

When a CBC flags something suspicious, the next step is usually a peripheral blood smear: a thin layer of blood spread on a glass slide and examined under a microscope. This is where a trained eye can identify abnormal cells that a machine counts but cannot describe. Blast cells, the immature white cells that accumulate in acute leukemias, are the primary targets. Their size, shape, and internal structures tell a hematologist a great deal about the type of leukemia involved.

One striking example comes from acute myeloid leukemia (AML). Certain AML subtypes produce cells packed with distinctive rod-shaped structures called Auer rods. In a case reported in Frontiers in Oncology, a blood smear revealed about 35% abnormal cells whose cytoplasm was filled with bundles of these rod-like bodies, a finding that immediately pointed toward a specific AML subtype and guided treatment decisions.³ Not every leukemia shows something so visually dramatic. Chronic lymphocytic leukemia (CLL) often presents with mature-looking but clonal lymphocytes, while chronic myeloid leukemia may show a spread of cells at every stage of development, almost like a textbook illustration of normal maturation gone haywire.

The smear also catches findings that are easy to confuse with leukemia but turn out to be something else entirely. Vitamin B12 deficiency, for instance, can cause such severe changes in blood cells, including pancytopenia, large red cells, and abnormal-looking white cells, that it has been mistaken for acute leukemia. In one published case, a patient was referred for induction chemotherapy at a major medical center before the actual culprit turned out to be a vitamin deficiency.⁴ The smear is powerful, but it requires context. A blood count that screams “leukemia” can occasionally turn out to be a nutritional deficit in disguise.

Automated Analyzer Flags

Before a human ever looks at the smear, the automated analyzer running the CBC generates its own flags and scatterplots, essentially graphical maps of how cells cluster by size and internal complexity. These machine-generated patterns are remarkably good at identifying abnormal populations. A study of 396 patients with leukemias and related malignancies found that the scatterplot patterns generated by an automated analyzer had a sensitivity of about 93% and a specificity of about 92% for detecting abnormal white cell populations.⁵

Some leukemia types produce especially recognizable patterns. About 80% of patients with acute promyelocytic leukemia (APML) in that study showed a characteristic scatterplot shape, and CML produced its own distinctive granulocyte-heavy plot. The analyzer also flags specific suspect categories, such as “variant lymphocyte” for lymphoid leukemias or “monoblast” for monocytic AML subtypes. These flags do not replace a pathologist’s eye, but they serve as an early warning system that helps labs prioritize which samples need urgent manual review. In busy hospitals, that triage function can shave hours or even days off the time to diagnosis.

Flow Cytometry for Identifying Cell Types

Once abnormal cells are spotted, the question shifts from “is something wrong?” to “what exactly are these cells?” Flow cytometry answers that question by tagging cells with fluorescent antibodies that stick to specific surface proteins, then passing them through a laser beam one at a time. Each cell’s fluorescent signature reveals what lineage it belongs to and how mature it is.

The panel of markers tested typically covers multiple cell lineages. T-cell markers like CD3, CD5, and CD7 identify T-cell leukemias. B-cell markers such as CD19, CD22, CD20, and CD10 point to B-cell diseases. Myeloid markers like CD13, CD14, and CD33 flag leukemias arising from the myeloid lineage.⁶ This is critical because leukemias that look similar under the microscope can behave very differently and require different treatments depending on which cell type is affected. Flow cytometry essentially sorts the cells into bins that dictate the treatment path.

Researchers have increasingly advocated for making flow cytometry a routine part of leukemia workups rather than a test reserved for ambiguous cases. A study using flow cytometry alongside standard blood counts found that identifying markers like CD3 and CD4 in leukemia patients improved diagnostic accuracy for distinguishing leukemia subtypes and identifying associated cytopenias.⁷ In many centers, flow cytometry on peripheral blood has become a standard part of the initial evaluation rather than something ordered only after a bone marrow biopsy.

Cytogenetics and FISH

Leukemias are driven by specific genetic abnormalities, and identifying those abnormalities is essential for diagnosis, prognosis, and treatment selection. Traditional cytogenetic analysis (also called karyotyping or G-banding) involves growing cells in culture and looking at their chromosomes under a microscope. This approach can spot large-scale changes like translocations, deletions, and extra chromosomes. The Philadelphia chromosome, the hallmark of CML, was famously discovered this way.

Fluorescence in situ hybridization, or FISH, takes a more targeted approach. It uses fluorescent probes that bind to specific regions of DNA, allowing technicians to check for known genetic changes without waiting for cells to grow. FISH and a molecular technique called RT-PCR both offer higher sensitivity for detecting the Philadelphia chromosome compared to traditional karyotyping, and they can be applied effectively to peripheral blood rather than requiring bone marrow.⁸ That said, the two specimen types are not interchangeable for every situation. A study comparing bone marrow and peripheral blood FISH results found that when bone marrow FISH was abnormal, peripheral blood FISH detected the abnormality about 69% of the time, but it missed about 31% of positive cases.⁹ And in CML specifically, one study concluded that while FISH on peripheral blood is useful, it cannot fully replace bone marrow analysis when detecting the Philadelphia chromosome.¹⁰

The practical takeaway: blood-based FISH is valuable and increasingly used, especially when a bone marrow sample is not immediately available, but it does have limits depending on how many abnormal cells are circulating.

Molecular Testing and Next-Generation Sequencing

Beyond chromosomal-level changes, leukemias also carry point mutations in specific genes, and identifying these mutations has become central to modern treatment. Techniques like Sanger sequencing and next-generation sequencing (NGS) can detect mutations in individual genes at high resolution. NGS in particular can identify cancer-associated mutations even when the mutated cells make up a small fraction of the sample, detecting as few as 1 to 5% of mutated cells depending on sequencing depth.¹¹

One gene commonly tested in AML is NPM1. Mutations in NPM1 are among the most frequent in AML and strongly influence prognosis and treatment planning. Identifying the exact type of NPM1 mutation matters not just for diagnosis but also for setting up the strategy to monitor the disease over time, tracking whether it is responding to treatment or beginning to come back. NGS can also reveal other driver mutations present in small subclones, giving doctors a more complete picture of the genetic landscape of the disease at the time of diagnosis.

Metabolic Blood Markers

Standard chemistry panels can also raise red flags for leukemia, even though they are not designed as cancer tests. Two markers stand out: lactate dehydrogenase (LDH) and uric acid. LDH is an enzyme released when cells break down rapidly, and uric acid rises when large numbers of cells are being destroyed and their contents spill into the bloodstream. In acute leukemia, both markers tend to climb sharply.

A study of patients with acute myeloid leukemia found that LDH, uric acid, and white blood cell levels all differed significantly among groups with varying disease severity, with LDH serving as a particularly useful indicator for guiding treatment decisions and assessing mortality risk.¹² Extremely elevated LDH can also signal tumor lysis syndrome, a dangerous condition that occurs when large numbers of cancer cells die rapidly, often after the start of chemotherapy, and flood the blood with potassium, phosphorus, and uric acid. Monitoring these metabolic markers before and during treatment helps oncologists anticipate and prevent this complication.

When Blood Tests Can Substitute for Bone Marrow

Bone marrow biopsy has long been considered the gold standard for leukemia diagnosis, but it is invasive and painful. A growing body of research asks whether peripheral blood, drawn from a simple arm vein, can provide equivalent information in certain situations.

For pediatric B-cell ALL, a study found that the markers most relevant to routine diagnostic classification, including CD19, CD10, CD34, and HLA-DR, showed greater than 95% concordance between bone marrow and peripheral blood, especially in patients with heavy disease burden (those with hemoglobin below 8 g/dL, where extensive marrow infiltration pushes plenty of leukemic cells into circulation).¹³ This finding is particularly relevant in resource-limited settings where rapid treatment decisions need to be made and bone marrow biopsy may introduce delays.

In adult AML, the story is broadly similar but with caveats. A comparison of bone marrow and peripheral blood in AML patients found that the two specimens showed largely similar drug-response profiles and cellular composition, though one specific cell type was present at much higher levels in bone marrow than in blood.¹⁴ The bottom line is that peripheral blood can increasingly stand in for bone marrow in specific diagnostic scenarios, but it has not replaced it entirely. Cases with low circulating blasts, mixed-lineage leukemias, or atypical features still benefit from the fuller picture that only bone marrow can provide.

Tracking the Disease After Treatment

Blood tests do not stop being useful once treatment begins. Minimal residual disease (MRD) monitoring, which aims to detect tiny numbers of leukemic cells left behind after therapy, has become a cornerstone of modern leukemia management. The goal is to catch a relapse at the molecular level, before it shows up on a CBC or causes symptoms.

Droplet digital PCR (ddPCR) is one of the most sensitive tools for this purpose. In patients with MLL-rearranged leukemia, ddPCR achieved detection limits as low as one leukemic cell in a million, and it identified disease at levels that standard quantitative PCR could not reliably measure.¹⁵ That extra sensitivity can make a real clinical difference: catching residual disease earlier allows doctors to adjust treatment before an overt relapse occurs.

An emerging alternative is monitoring cell-free DNA, tiny fragments of DNA released by dying cells into the bloodstream. In AML patients after stem cell transplant, sequencing of cell-free DNA detected residual leukemia with higher sensitivity than standard chimerism analysis (the test typically used to see whether the donor’s cells are still dominant).¹⁶ Both genetic and epigenetic changes in this circulating tumor DNA can be measured, providing not just a yes-or-no answer about residual disease but a dynamic picture of how the leukemia is evolving over time.¹⁷

Liquid Biopsies and the Future of Blood-Based Leukemia Testing

The broader concept tying these newer approaches together is the liquid biopsy: using a blood draw to extract the same molecular information that previously required tissue. For solid tumors like lung or breast cancer, liquid biopsies have already entered routine clinical practice. For leukemia, they occupy an interesting position because the cancer already lives in the blood, meaning the raw material is always available.

The clinical potential extends across the entire disease course. Cell-free DNA and circulating tumor DNA can serve as biomarkers for initial diagnosis, prognosis, treatment monitoring, and MRD detection across myeloid and lymphoid leukemias alike.¹⁸ The appeal is obvious: a single blood draw at regular intervals could potentially replace a series of bone marrow biopsies, each of which is uncomfortable and resource-intensive. The technology is not yet standardized enough to replace traditional methods across the board, but pilot studies continue to demonstrate its clinical promise, and it is likely to become a larger part of routine care in the next decade.

Pitfalls That Lead to False Alarms

Not every alarming blood result means leukemia, and clinicians need to account for technical artifacts and look-alike conditions before launching a full diagnostic workup. On the technical side, the way a blood sample is handled before analysis can produce misleading counts. White blood cell counts may appear falsely low if cells clump together in the collection tube, or falsely high if cryoglobulins, lipids, or platelet aggregates interfere with the analyzer.¹⁹ Hemoglobin readings can be thrown off by similar pre-analytical problems. A lab technician spotting a bizarre CBC result will often re-run the sample or request a fresh draw before anyone raises the alarm.

On the clinical side, a handful of non-malignant conditions produce blood pictures eerily similar to leukemia. Severe infections can drive white counts high enough to mimic chronic myeloid leukemia, a situation sometimes called a leukemoid reaction. Vitamin B12 deficiency, as noted earlier, can produce immature-looking cells that fool even experienced clinicians.⁴ Autoimmune conditions add another layer of complexity: patients with chronic lymphocytic leukemia, for instance, develop autoimmune hemolytic anemia in roughly 7 to 10% of cases, where the immune system destroys the patient’s own red blood cells. This overlap means that an unexplained drop in hemoglobin in a CLL patient might reflect disease progression, an autoimmune complication, or both.

How Pediatric and Adult Leukemia Blood Profiles Differ

Children and adults do not get the same types of leukemia in the same proportions, and this shapes what clinicians expect to see on blood tests. In a comparative analysis of 283 cases, pediatric leukemia was dominated by ALL at about 49%, followed by AML at about 20%. In adults, CML was the most common type at about 37%, followed by AML at about 26%.²

The blood count patterns reflect these differences. Anemia was nearly universal in both children and adults. But thrombocytopenia, or low platelet counts, tended to be more severe in pediatric ALL and AML, while adults with CML often maintained relatively normal platelet levels. For a pediatrician, then, the combination of severe anemia, very low platelets, and circulating blasts strongly suggests ALL until proven otherwise. For an internist seeing an adult, a grossly elevated white count with a full range of maturing cells and normal platelets points more toward CML. These patterns are statistical tendencies, not rules, but they help guide the urgency and direction of follow-up testing.

The age-based differences also influence which advanced tests are ordered first. Because pediatric B-ALL is so common and carries specific genetic markers with well-defined prognostic significance, flow cytometry and cytogenetic panels for children often include markers optimized for that disease. In adults, the wider spread of leukemia types means the initial molecular panel tends to be broader, looking for CML-associated translocations, AML-associated mutations, and CLL markers simultaneously.